Alaunos Therapeutics (TCRT) vs Vistagen Therapeutics (VTGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Vistagen Therapeutics is the larger company by market cap ($7.6 million vs $7.0 million), about 1.1 times the size. Vistagen Therapeutics converts more of its revenue into profit, with a net margin of -5491.3% versus -83520.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TCRT | VTGN |
|---|---|---|
| Share price | $1.66 | $0.1636 |
| Market cap | $6.99M | $7.56M |
| 1-day change | +3.75% | -12.33% |
| YTD return | — | -75.21% |
| 1-year return | — | -96.44% |
| 5-year return | — | -99.72% |
| EPS (TTM) | $-1.76 | $-1.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $5.00K | $1.27M |
| Revenue growth (YoY) | -50.00% | +161.11% |
| Net income (latest FY) | $-4.18M | $-69.69M |
| Operating margin | -84500.00% | -5683.69% |
| Net margin | -83520.00% | -5491.33% |
| 52-week high | $4.50 | $5.14 |
| 52-week low | $0.72 | $0.16 |
| Distance from 52-week high | -63.11% | -96.82% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +511.25% |
| Average volume | 7.56M | 10.30M |
| Shares outstanding | 4.21M | 46.19M |
| Employees | 1 | 41 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Vistagen Therapeutics is more profitable, keeping -5491.3 cents of every revenue dollar as net income versus -83520.0 cents for Alaunos Therapeutics.
- Vistagen Therapeutics grew revenue faster in its latest fiscal year (+161.11% vs -50.00%).
About Alaunos Therapeutics
TCRT stock →Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs.
Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees
About Vistagen Therapeutics
VTGN stock →Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase IIa clinical trial to treat major depressive disorder.
Health Care · Biotechnology: Pharmaceutical Preparations · 41 employees
TCRT vs VTGN FAQ
Which is bigger, Alaunos Therapeutics or Vistagen Therapeutics?
Vistagen Therapeutics (VTGN) is larger, with a market capitalization of $7.56M compared with $6.99M for Alaunos Therapeutics (TCRT).
Are Alaunos Therapeutics and Vistagen Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.